测量单克隆抗体疗法的影响
Ka Keat Lim1, Kenrick Ng2, Sathiyaa Balachandran3
1Department of Population Health Sciences, King's College London, London, United Kingdom.
Frontiers in medicine
|December 4, 2023
概括
单克隆抗体 (Mab) 治疗提供了显著的健康益处,但成本昂贵. 这项研究开发了一种估计Mab药物效应的方法,发现现实世界结果与临床试验一致,并评估健康策略的净货币效益.
科学领域:
- 药物经济学 药物经济学
- 卫生技术评估 卫生技术评估
- 在瘤学瘤学.
- 类风湿病学 类风湿病学
背景情况:
- 单克隆抗体 (Mab) 治疗显著改善患者的治疗结果,但价格昂贵,导致在采用时犹.
- 需要一种系统的方法来估计Mab药物的一般作用,以告知健康策略,并最大限度地利用科学发现的好处.
研究的目的:
- 评估一种方法来估计已建立的单克隆抗体 (Mab) 疗法对健康和经济的影响.
- 为了比较现实世界数据 (RWD) 结果与对 Mab 治疗的随机对照试验 (RCT) 数据.
主要方法:
- 对RWD和RCT数据进行了系统的文献审查和元分析,用于瘤学和风湿病学中的五种Mab疗法.
- 使用马尔科夫模型进行经济建模,以估计每个Mab方案的净货币收益 (NMB).
主要成果:
- 分析显示,RWD中观察到的健康结果与RCT中预期的结果之间存在密切一致.
- 经济建模表明,三项马布计划的净利为正面,两项马布计划的利为负面.
- 由于NHS数据访问有限,NMB估计的准确性受到假设的影响.
结论:
- 随机试验结果可靠地预测现实世界的Mab治疗经验.
- 描述的NMB计算算法提供了一个有价值的健康影响测量,取决于数据输入的准确性.
- 建议建立一个全面的,可访问的数据库和分析系统,用于卫生服务中的所有Mab治疗.
相关概念视频
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Hybridoma Technology
14.8K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
14.8K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
143
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
143
Tumor Immunotherapy
529
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
529
Antibody Actions
1.1K
Antibodies, or immunoglobulins, are critical players in the immune system's arsenal against invading pathogens. Produced by B cells and plasma cells, their primary role is to detect and bind to specific antigens, molecules found on the surface of pathogens like bacteria or viruses. Beyond antigen recognition, antibodies perform several vital functions that contribute to immune defense.
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
1.1K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K


